JPRN-UMIN000002405CompletedPhase 2
Photodynamic therapy with one third dose verteporfin for central serous chorioretinopathy:Prospective intervention trial - Photodynamic therapy with one third dose verteporfin for central serous chorioretinopathy
agoya University School of Medicine Department of Ophthalmology0 sites6 target enrollmentStarted: October 1, 2009Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Enrollment
- 6
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to 70years-old (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1. drug allery to verteporfin 2. pregnant or expecting pregnancy 3. porphyria, or hypersensitivity to artificial illumination 4. macular diseases other than CSC 5. others (inappropriate case judged by investigator or subinvestigators)
Investigators
Similar Trials
Completed
Phase 2
Photodynamic therapy with two third dose verteporfin for central serous chorioretinopathy:Prospective intervention trialCentral serous chorioretinopathyJPRN-UMIN000002770agoya University School of Medicine Department of Ophthalmology6
Completed
Phase 2
Photodynamic therapy with half dose verteporfin for central serous chorioretinopathy:Prospective intervention trialCentral serous chorioretinopathyJPRN-UMIN000002229agoya University School of Medicine Department of Ophthalmology10
Active, not recruiting
Not Applicable
Initial Combination of Photodynamic Therapy with Verteporfin and Intravitreal Administration of Ranibizumab in Patients with Subfoveal Choroidal Neovascularisation due to Age-related Macular DegeneratioThe case-series is designed to evaluate the safety and efficacy of intravitreal ranibizumab used in combination with verteporfin photodynamic therapy (Visudyne) for the treatment of subfoveal CNV secondary to AMDEUCTR2006-004978-27-ATZentralklinikum St. Pölten
Active, not recruiting
Phase 1
A Phase 1 Trial of Verteporfin Photodynamic Therapy in Unresectable Pancreatic Carcinoma (VERTPAC-01 study) - VERTPAC-01EUCTR2006-004097-28-GBniversity College Hospitals NHS Foundation Trust/ University College London12
Completed
Not Applicable
Reduced fluence photodynamic therapy combined with intravitreal anti-vascular endothelial growth factor antibody for age-related macular degeneration.Age-related macular degenerationJPRN-UMIN000004562Yamagata University Faculty of Medicine50